Cannabis And Its Derived products, or medicinal marijuana, is a therapy that has garnered much national attention in recent years. Controversies surrounding legal, ethical, and societal implications associated with use; safe administration, packaging, and dispensing; adverse health consequences and deaths attributed to marijuana intoxication; and therapeutic indications based on limited clinical data represent some of the complexities associated with this treatment. Marijuana is currently recognized by the U.S. Drug Enforcement Agency’s (DEA’s) Comprehensive Drug Abuse Prevention and Control Act (Controlled Substances Act) of 1970 as a Schedule I controlled substance, defined as having a high potential for abuse, no currently accepted medicinal use in treatment in the United States, and a lack of accepted safety data for use of the treatment under medical supervision.
Cannabis is the most commonly cultivated, trafficked, and abused illicit drug worldwide; according to the World Health Organization (WHO), marijuana consumption has an annual prevalence rate of approximately 147 million individuals or nearly 2.5% of the global population. In 2014, approximately 22.2 million Americans 12 years of age or older reported current cannabis use, with 8.4% of this population reporting use within the previous month.Further, a recent Quinnipiac University poll concluded 54% of American voters surveyed would favor the legalization of cannabis without additional constraints, while 81% of respondents favored legalization of cannabis for medicinal purposes.6 Limited data suggest that health care providers also may consider this therapy in certain circumstances.7–9 In the United States, cannabis is approved for medicinal use in 28 states, the District of Columbia, Guam, and Puerto Rico as of January 2001.
Regulatory Resources for Cannabis And Its Derived products:
- Scientific Conference on November 19, 2020: CBD and Other Cannabinoids: Sex and Gender Differences in Use and Responses
- Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry
- Information on CBD Data Collection and Submission
- FDA and Cannabis: Research and Drug Approval Process
- FDA Regulation of Dietary Supplement & Conventional Food Products Containing Cannabis and Cannabis-Derived Compounds
Cannabis And Its Derived products
Cannabis sativa derivatives (marijuana, hashish) are currently the most frequently self-administered “soft narcotics” worldwide. Δ9-Tetrahydrocannabinol (THC), as other psychoactive substances, leads to a chronic and recurrent central nervous system (CNS) disease, complex in terms of its etiology, molecular mechanisms, clinical course, and treatment. This phenomenon is thought to be influenced by several concurrently acting genetic, molecular, psychological, and social factors, but the molecular aspects of this process are not fully known yet.